Gore ASSURED Clinical Study results through 36 months demonstrate 100 percent closure success * with the GORE ® CARDIOFORM ASD Occluder, and consistent safety outcomes † across a broad range of ASD ...
FLAGSTAFF, Ariz.- W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration's (FDA's) premarket approval (PMA) of the GORE® CARDIOFORM ASD Occluder for the percutaneous closure of ...
Long-term survival after transcatheter closure of secundum atrial septal defects (ASD) is similar to that achieved after surgical closure, but the former method is far more likely to require ...
Three months of clopidogrel given on top of aspirin was associated with a reduced frequency of migraine in patients who had undergone transcatheter closure of an atrial septal defect (ASD) in the ...
February 7, 2008 (Chicago, IL) - Doctors and regulators concerned about the spike in off-label patent foramen ovale (PFO) closure procedures now have some numbers to fall back on. A research letter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback